| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Rewards
Risk Analysis
Community Narratives
Narratives bring a range of perspectives from our community.
Navigating Growth And Challenges, The Bright Future Of Oncology And Innovative Therapies
US$142.7
FV
20.2% undervalued intrinsic discount6.34%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
9 days agoauthor updated this narrative
Merck & Co., Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$113.82 |
| 52 Week High | US$134.63 |
| 52 Week Low | US$99.14 |
| Beta | 0.39 |
| 11 Month Change | -10.88% |
| 3 Month Change | -10.74% |
| 1 Year Change | 7.65% |
| 33 Year Change | 50.58% |
| 5 Year Change | 34.33% |
| Change since IPO | 10,017.33% |
Recent News & Updates
Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 01
Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins
Jul 31Recent updates
Merck & Co., Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
Aug 01Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins
Jul 31Merck Q2 Earnings Preview: We Need To Talk About Keytruda's LOE
Jul 24Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet
Jul 18Merck: Positive Developments, But Watch The Q2 Earnings
Jul 12Merck: Among The Best Health Care GARP Plays Today
Jul 03What Merck & Co., Inc.'s (NYSE:MRK) P/S Is Not Telling You
Jun 30Dividends And Innovation: Why Merck Is A Healthcare Stock Worth Buying
Jun 10Merck Stock: Still Discounted To Graham P/E
May 29Merck & Co., Inc.'s (NYSE:MRK) CEO Compensation Looks Acceptable To Us And Here's Why
May 22Shareholder Returns
| MRK | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.6% | -2.2% | 2.1% |
| 1Y | 7.7% | 16.5% | 20.5% |
Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned 16.5% over the past year.
Return vs Market: MRK underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| MRK volatility | |
|---|---|
| MRK Average Weekly Movement | 4.0% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 14.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: MRK has not had significant price volatility in the past 3 months.
Volatility Over Time: MRK's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1891 | 71,000 | Rob Davis | www.merck.com |
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.
Merck & Co., Inc. Fundamentals Summary
| MRK fundamental statistics | |
|---|---|
| Market cap | US$286.54b |
| Earnings (TTM) | US$13.74b |
| Revenue (TTM) | US$62.48b |
21.0x
P/E Ratio4.6x
P/S RatioIs MRK overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRK income statement (TTM) | |
|---|---|
| Revenue | US$62.48b |
| Cost of Revenue | US$15.07b |
| Gross Profit | US$47.41b |
| Other Expenses | US$33.68b |
| Earnings | US$13.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Oct 31, 2024
| Earnings per share (EPS) | 5.42 |
| Gross Margin | 75.89% |
| Net Profit Margin | 21.98% |
| Debt/Equity Ratio | 84.7% |
How did MRK perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield55%
Payout RatioDoes MRK pay a reliable dividends?
See MRK dividend history and benchmarks| Merck dividend dates | |
|---|---|
| Ex Dividend Date | Sep 16 2024 |
| Dividend Pay Date | Oct 07 2024 |
| Days until Ex dividend | 45 days |
| Days until Dividend pay date | 66 days |
Does MRK pay a reliable dividends?
See MRK dividend history and benchmarks